These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Author: Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L.
    Journal: Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179.
    Abstract:
    The oral administration of 150 micrograms desogestrel and 30 micrograms ethinyl estradiol (EE2) increases (P less than 0.001) serum concentrations of sex-hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG), whereas treatment with 150 micrograms levonorgestrel and 30 micrograms EE2 only increases serum CBG concentrations. No changes in serum albumin concentrations occurred during or after treatment with either preparation, and increases in SHBG and CBG returned to the pretreatment values 1 month after treatment ceased. The serum distribution of levonorgestrel was unchanged during treatment, whereas the increase in serum SHBG concentrations after treatment with the preparation containing desogestrel decreased (P less than 0.001) the percentage of non-protein-bound 3-keto- desogestrel and the percentage of albumin-bound 3-keto- desogestrel but increased (P less than 0.001) the SHBG-bound fraction. Oral contraceptives containing either progestogen decrease the mean serum non-protein-bound testosterone concentrations, especially during treatment with desogestrel (P less than 0.001), and desogestrel may therefore by the more appropriate progestogen for the treatment of women prone to androgenic side effects. The oral administration of 150 mcg desogestrel and 30 mcg ethinly estradiol (EE2) increases (P0.001) serum concentrations of sex hormone binding globulind (SHBG) and corticosteroid-binding globulin (CBG) whereas treatment with 150 mcg levonorgestrel and 30 mcg EE2 only increases serum CBG concentrations. No changes in serum albumin concentrations occurred during or after treatment with either preparation, and increases in SHBG and CBG returned to the pretreatment values 1 month after treatment ceased. The serum distribution of levonorgestrel was unchanged during treatment, whereas the increase in serum SHBG concentrations after treatment with the preparation containing desogestrel decreased (P0.001) the percentage of nonprotein-bound 3-keto-desogestrel and the precentage of albumin-bound 3-ketodesogestrel but increased (P0.001) the SHBG-bound fraction. Oral contraceptives containing either progestogen decrease the mean serum nonprotein-bound testosterone concentratious, especially during treatment with desogesgtrel (P0.001), and desogestrel may therefore be the more appropriate progestogen for the treatment of women who are prone to androgenic side effects.
    [Abstract] [Full Text] [Related] [New Search]